IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING
Open Access
- 1 March 2004
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 32 (3) , 295-304
- https://doi.org/10.1124/dmd.32.3.295
Abstract
Human liver microsomes (HLMs) are frequently utilized in drug discovery to predict the human clearance of a compound. The extent to which the incubation conditions affect the accuracy of a human clearance prediction was determined for bufuralol. HLMs were preincubated at 37°C for varying times (5–120 min) with and without NADPH, and the remaining enzyme activity was determined by incubating compounds that have been characterized to be selective for individual cytochromes P450 or flavin-containing monooxygenase 3. CYP2D6, the high-affinity component of bufuralol metabolism, was shown to be the least stable of the isoforms studied. The loss of CYP2D6 activity was further examined by determining the kinetics of 1′-hydroxybufuralol formation after different preincubation time periods, by using reactive oxygen species (ROS) scavengers, and by utilizing Western blotting techniques. A 3-fold decrease in Vmax was observed over 2 h, whereas the Km remained constant. ROS scavengers were able to block enzyme lability, and Western blots revealed no apparent loss of immunoreactive enzyme. The protein binding of bufuralol was determined in HLMs, recombinant CYP2D6, and human plasma. A prediction of theoretical bufuralol concentrations over a 120-min incubation that incorporated enzyme lability was performed and shown to be closer to actual data than if enzyme lability were ignored. Finally, a similar prediction using literature bufuralol data, coupled with the observed protein binding data, was used to illustrate that the most accurate predictions of bufuralol clearance are obtained when the amount of protein in the incubation is kept to a minimum and the overall incubation time is less than 20 min.Keywords
This publication has 24 references indexed in Scilit:
- Catalytic Specificity of CYP2D Isoforms in Rat and HumanDrug Metabolism and Disposition, 2002
- Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -independent pathwaysBiochemical Journal, 2001
- NADPH-Dependent Microsomal Electron Transfer Increases Degradation of CYP2E1 by the Proteasome Complex: Role of Reactive Oxygen SpeciesArchives of Biochemistry and Biophysics, 1999
- In Vitro MetabolismPublished by Taylor & Francis ,1999
- Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.Pharmaceutical Research, 1999
- In vitro assessment of human cytochrome P450Xenobiotica, 1998
- Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidationBiochemical Pharmacology, 1987
- High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liverAnalytical Biochemistry, 1987
- Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolEuropean Journal of Clinical Pharmacology, 1985
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984